Marta Orozco Belinchon, Medical Oncologist at MD Anderson Cancer Center Madrid, shared a post on X:
“In metastatic disease, one of the key questions:
Should we rechallenge with EV plus pembrolizumab after prior perioperative use?
Half of the experts say yes. The other half, no. Evidence is still limited… but the clinical need is real.
What do you think?”
Other articles about MD Anderson Cancer Center on OncoDaily.
